April 2026
1. ELLS Z, Meyer C, Kimura K, Wilhalme H, et al
   Dosimetry Analysis of (177)Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
   J Nucl Med. 2026 Apr 2:jnumed.125.271467. doi: 10.2967/jnumed.125.271467.
   

   >> Share

   
   March 2026
2. HOANG TT, Bauer D, Ingham A, Miranda IC, et al
   Delta-like Ligand 3-Directed (225)Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.
   J Nucl Med. 2026 Mar 26:jnumed.125.271302. doi: 10.2967/jnumed.125.271302.
   

   >> Share

   
   
3. GOGEBAKAN KC, Kunst N, Ghodsi A, Owens L, et al
   Cost-Effectiveness Analysis of (177)Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.
   J Nucl Med. 2026 Mar 19:jnumed.125.271825. doi: 10.2967/jnumed.125.271825.
   

   >> Share

   
   
4. GHODSI A, Demirci RA, Gulati R, Nelson PS, et al
   Prognostic Value of Cycle 1 SPECT SUV(mean) in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA-617.
   J Nucl Med. 2026 Mar 12:jnumed.125.271593. doi: 10.2967/jnumed.125.271593.
   

   >> Share

   
   
5. MORADPOUR M, Moradi Tuchayi A, Yadav S, Jiang F, et al
   Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.
   J Nucl Med. 2026 Mar 5:jnumed.125.271296. doi: 10.2967/jnumed.125.271296.
   

   >> Share

   
   February 2026
6. BIO IDRISSOU M, Aguiar Ferreira C, Comas Rojas H, Lambert Lepesevich LH, et al
   Preclinical Evaluation of [(177)Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer.
   J Nucl Med. 2026 Feb 26:jnumed.125.271543. doi: 10.2967/jnumed.125.271543.
   

   >> Share

   
   
7. KIANI I, Siri MA, Babaei M, Aliasghari MM, et al
   Quantitative PSMA PET Biomarkers for Predicting Response to (177)Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis.
   J Nucl Med. 2026 Feb 26:jnumed.125.270872. doi: 10.2967/jnumed.125.270872.
   

   >> Share

   
   
8. CHAUSSE G, Hou X, Uribe C, Harsini S, et al
   First-in-Human Evaluation of [(68)Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer.
   J Nucl Med. 2026 Feb 26:jnumed.123.266357. doi: 10.2967/jnumed.123.266357.
   

   >> Share

   
   
9. PEPIN A, Doucette A, Narayan VK, Maxwell KN, et al
   Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
   J Nucl Med. 2026 Feb 19:jnumed.125.270757. doi: 10.2967/jnumed.125.270757.
   

   >> Share

   
   
10. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging.
    J Nucl Med. 2026 Feb 12:jnumed.125.271423. doi: 10.2967/jnumed.125.271423.
    

    >> Share

    
    
11. NIKITAS J, Holzgreve A, Juarez J, Kimura K, et al
    Phase 2 Prospective Trial of Retreatment with [(177)Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.
    J Nucl Med. 2026 Feb 12:jnumed.125.271231. doi: 10.2967/jnumed.125.271231.
    

    >> Share

    
    January 2026
12. LI Y, Yang J, Chen B, Xiao L, et al
    Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.
    J Nucl Med. 2026 Jan 29:jnumed.125.271410. doi: 10.2967/jnumed.125.271410.
    

    >> Share

    
    
13. WIDJAJA L, Siegmund SC, Gildehaus FJ, Delker A, et al
    PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [(225)Ac]Ac-PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2026 Jan 29:jnumed.125.270677. doi: 10.2967/jnumed.125.270677.
    

    >> Share

    
    
14. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study.
    J Nucl Med. 2026 Jan 29:jnumed.125.271173. doi: 10.2967/jnumed.125.271173.
    

    >> Share

    
    
15. ABDEL-WAHAB M, Giammarile F
    Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.
    J Nucl Med. 2026 Jan 8:jnumed.125.271268. doi: 10.2967/jnumed.125.271268.
    

    >> Share

    
    December 2025
16. MOAR EF, Keilholz M, Sheikh GT, Werner RA, et al
    PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOG.
    J Nucl Med. 2025 Dec 30:jnumed.125.271324. doi: 10.2967/jnumed.125.271324.
    

    >> Share

    
    
17. MAURER A, Muehlematter UJ, Sivakumar T, Mortezavi A, et al
    High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes?
    J Nucl Med. 2025 Dec 4:jnumed.125.271318. doi: 10.2967/jnumed.125.271318.
    

    >> Share

    
    
18. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [(177)Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270916. doi: 10.2967/jnumed.125.270916.
    

    >> Share

    
    November 2025
19. GABLER N, Kirchhoff S, Sauter A, Heck M, et al
    [(18)F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.
    J Nucl Med. 2025 Nov 25:jnumed.125.270435. doi: 10.2967/jnumed.125.270435.
    

    >> Share

    
    
20. BUCH-OLSEN KM, Vilstrup MH, Hansen S, Poulsen MH, et al
    Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [(18)F]PSMA-1007 PET/CT and [(18)F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management.
    J Nucl Med. 2025 Nov 25:jnumed.125.270710. doi: 10.2967/jnumed.125.270710.
    

    >> Share

    
    
21. WANG G, Lai Y, Chen D, Jin W, et al
    First-in-Human PET Imaging of Prostate Cancer Using [(68)Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [(68)Ga]Ga-AZ-NI-093.
    J Nucl Med. 2025 Nov 20:jnumed.125.270703. doi: 10.2967/jnumed.125.270703.
    

    >> Share

    
    
22. GHEZZO S, Mapelli P, Cogrossi LL, Samanes Gajate AM, et al
    Diagnostic Accuracy of Fully Hybrid PET/MRI with [(68)Ga]Ga-PSMA-11 and [(68)Ga]Ga-RM2 in Detecting Primary Prostate Cancer: A Phase 2 Trial with Histology as Gold Standard.
    J Nucl Med. 2025 Nov 20:jnumed.125.269782. doi: 10.2967/jnumed.125.269782.
    

    >> Share

    
    
23. HARTENBACH M, Rasul S, Grubmuller B, Kramer G, et al
    PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.
    J Nucl Med. 2025 Nov 20:jnumed.125.270404. doi: 10.2967/jnumed.125.270404.
    

    >> Share

    
    
24. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, International IAEA Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270537. doi: 10.2967/jnumed.125.270537.
    

    >> Share

    
    
25. HOEKSTRA RJ, Peeters L, Beulens A, Roef MJ, et al
    Prospective Histopathologic Comparison Between [(18)F]PSMA-1007 PET/CT and [(18)F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270650. doi: 10.2967/jnumed.125.270650.
    

    >> Share

    
    
26. ORTNER G, Hoderlein X, Barbato F, Beyersdorff D, et al
    The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270667. doi: 10.2967/jnumed.125.270667.
    

    >> Share

    
    
27. MIRSHAHVALAD SA, Iravani A, Fendler WP, Maurer T, et al
    Rechallenge and Extended [(177)Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270889. doi: 10.2967/jnumed.125.270889.
    

    >> Share

    
    
28. KRAUSEWITZ P, Essler M, Gaertner FC, Attenberger U, et al
    Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP Trial.
    J Nucl Med. 2025 Nov 6:jnumed.125.271344. doi: 10.2967/jnumed.125.271344.
    

    >> Share

    
    October 2025
29. DJAILEB L, Farolfi A, Rauscher I, Haghighatian M, et al
    Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [(177)Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Oct 30:jnumed.125.270239. doi: 10.2967/jnumed.125.270239.
    

    >> Share

    
    
30. RAHBAR K, Giesel FL, Herrmann K, Yun M, et al
    Efficacy of [(18)F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Oct 23:jnumed.125.269818. doi: 10.2967/jnumed.125.269818.
    

    >> Share

    
    
31. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025 Oct 16:jnumed.125.270825. doi: 10.2967/jnumed.125.270825.
    

    >> Share

    
    
32. KOEHLER D, Shenas F, Sauer M, Apostolova I, et al
    PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.
    J Nucl Med. 2025 Oct 16:jnumed.125.270242. doi: 10.2967/jnumed.125.270242.
    

    >> Share

    
    
33. MADSEN C, Zacho HD, Fuglo D, Nielsen K, et al
    (18)F-PSMA PET/CT Versus (18)F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study.
    J Nucl Med. 2025 Oct 9:jnumed.125.270822. doi: 10.2967/jnumed.125.270822.
    

    >> Share

    
    
34. CHEN DC, Buteau JP, Papa N, Akhurst T, et al
    Prognostic Value of Initial Imaging and PSA Change with [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
    J Nucl Med. 2025 Oct 9:jnumed.125.270804. doi: 10.2967/jnumed.125.270804.
    

    >> Share

    
    
35. TEUNISSEN FR, Oprea-Lager DE, Peters SMB, Smeenk RJ, et al
    Current Developments in Combining External-Beam Radiotherapy and (177)Lu-Labeled PSMA Ligands for Prostate Cancer Treatment.
    J Nucl Med. 2025 Oct 3:jnumed.125.270465. doi: 10.2967/jnumed.125.270465.
    

    >> Share

    
    
36. SARTOR O, Emmett L, Herrmann K
    Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.271144. doi: 10.2967/jnumed.125.271144.
    

    >> Share

    
    
37. KUCUK NO, Coskun N, Araz M, Alan Selcuk N, et al
    Initial Multicenter Experience with [(161)Tb]Tb-PSMA in [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.
    J Nucl Med. 2025 Oct 3:jnumed.125.270952. doi: 10.2967/jnumed.125.270952.
    

    >> Share

    
    
38. KARMANN A, Rose S, Herrmann K, Kratochwil C, et al
    alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.270940. doi: 10.2967/jnumed.125.270940.
    

    >> Share

    
    
39. HOYVIK AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, et al
    Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.
    J Nucl Med. 2025 Oct 3:jnumed.125.270444. doi: 10.2967/jnumed.125.270444.
    

    >> Share

    
    
40. 
    Biomarkers in Prostate Cancer: What's in the Blood?
    J Nucl Med. 2025;66:6A.
    

    >> Share

    
    September 2025
41. LIU F, Monterosso ME, Boucher D, Shakti S, et al
    Preclinical Evaluation of [(212)Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted alpha-Therapy for Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.269707. doi: 10.2967/jnumed.125.269707.
    

    >> Share

    
    
42. HADASCHIK B, Gillessen S, Sartor O
    (177)Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270836. doi: 10.2967/jnumed.125.270836.
    

    >> Share

    
    
43. GIRI VK, Kolodny GM, Garnick MB
    First-Line [(177)Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270704. doi: 10.2967/jnumed.125.270704.
    

    >> Share

    
    
44. PEPIN A, Doucette A, Vapiwala N, Narayan VK, et al
    Safety of the Combination of External Beam Radiotherapy with (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270316. doi: 10.2967/jnumed.125.270316.
    

    >> Share

    
    
45. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with (177)Lu-PSMA: A Retrospective, Single-Center Study.
    J Nucl Med. 2025 Sep 25:jnumed.125.269971. doi: 10.2967/jnumed.125.269971.
    

    >> Share

    
    
46. BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
    [(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
    J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
    

    >> Share

    
    
47. KUNSCH J, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [(177)Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 degrees Cadmium-Zinc-Telluride SPECT.
    J Nucl Med. 2025 Sep 11:jnumed.125.270358. doi: 10.2967/jnumed.125.270358.
    

    >> Share

    
    August 2025
48. HOLZGREVE A, Delker A, Ells Z, Brosch-Lenz J, et al
    Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of (177)Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol.
    J Nucl Med. 2025 Aug 28:jnumed.125.269495. doi: 10.2967/jnumed.125.269495.
    

    >> Share

    
    
49. ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al
    Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
    J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
    

    >> Share

    
    
50. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    

    >> Share

    
    July 2025
51. DENIS CS, Cousin F, De Laere B, Vanwelkenhuyzen J, et al
    Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Jul 31:jnumed.125.269729. doi: 10.2967/jnumed.125.269729.
    

    >> Share

    
    
52. CHEN Y, Zhang X, Wang X, Liu Y, et al
    Interspecies Variability in Biodistribution and PET Imaging Performance of [(18)F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer.
    J Nucl Med. 2025 Jul 17:jnumed.125.270069. doi: 10.2967/jnumed.125.270069.
    

    >> Share

    
    
53. KOHAN A, Metser U, Luke W, Rashid M, et al
    A Prospective Provincial Registry of (18)F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.
    J Nucl Med. 2025 Jul 3:jnumed.125.269653. doi: 10.2967/jnumed.125.269653.
    

    >> Share

    
    
54. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    

    >> Share

    
    June 2025
55. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
    J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
    

    >> Share

    
    
56. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
    Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
    J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
    

    >> Share

    
    
57. SCHMITL S, Kretschmer-Chott E, Patronas EM, Kramer G, et al
    Efficacy, Safety, Blood Kinetics, and (213)Bi Distribution Studies of [(225)Ac]Ac-SibuDAB in Prostate Cancer Patients.
    J Nucl Med. 2025 Jun 5:jnumed.125.269655. doi: 10.2967/jnumed.125.269655.
    

    >> Share

    
    
58. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
    Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
    

    >> Share

    
    
59. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
    Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
    J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
    

    >> Share

    
    
60. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    

    >> Share

    
    May 2025
61. VAN RIEL JHHM, Donswijk ML, Brouwer C, Gerritsen WR, et al
    Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with (223)Ra Therapy in Daily Practice.
    J Nucl Med. 2025 May 22:jnumed.125.269746. doi: 10.2967/jnumed.125.269746.
    

    >> Share

    
    
62. SATAPATHY S, Das CK, Goyal S, Sood A, et al
    (177)Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial.
    J Nucl Med. 2025 May 22:jnumed.125.269913. doi: 10.2967/jnumed.125.269913.
    

    >> Share

    
    April 2025
63. HARSINI S, Soleimani M, Wilson D, Uribe C, et al
    A Phase I/II Study of [(177)Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.
    J Nucl Med. 2025 Apr 30:jnumed.124.269064. doi: 10.2967/jnumed.124.269064.
    

    >> Share

    
    
64. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    

    >> Share

    
    
65. DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al
    Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT.
    J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361.
    

    >> Share

    
    March 2025
66. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    

    >> Share

    
    
67. YANG H, Wang J, Wen X, Guo H, et al
    Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives (68)Ga/(177)Lu-LNC1011 as Prostate Cancer Theranostics.
    J Nucl Med. 2025 Mar 20:jnumed.124.268959. doi: 10.2967/jnumed.124.268959.
    

    >> Share

    
    
68. TANG W, Qi L, Chen M, Zhang Y, et al
    Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study.
    J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189.
    

    >> Share

    
    
69. BERNER K, Hernes E, Kvassheim M, Revheim ME, et al
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299.
    

    >> Share

    
    
70. JEWELL KE, Buteau JP, Medhurst E, Kwan EM, et al
    Safety and Efficacy of 20 Cycles of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269447. doi: 10.2967/jnumed.124.269447.
    

    >> Share

    
    
71. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    

    >> Share

    
    
72. JOHNSTONE CN, Osellame LD, Cao Z, McDonald AF, et al
    DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of (177)Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
    J Nucl Med. 2025;66:385-390.
    

    >> Share

    
    February 2025
73. TURCO F, Gillessen S, Herrmann K, Paone G, et al
    Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730.
    

    >> Share

    
    
74. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    

    >> Share

    
    
75. EIFER M, Sutherland DEK, Goncalves I, Buteau JP, et al
    Therapy-Related Myeloid Neoplasms After [(177)Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.
    J Nucl Med. 2025 Feb 20:jnumed.124.268640. doi: 10.2967/jnumed.124.268640.
    

    >> Share

    
    
76. KOSTOS L, Buteau JP, Kong G, Tran B, et al
    Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269252. doi: 10.2967/jnumed.124.269252.
    

    >> Share

    
    
77. LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al
    Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318.
    

    >> Share

    
    
78. DERLIN T, Widjaja L, Harke NN, Czerner C, et al
    (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319.
    

    >> Share

    
    
79. VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al
    Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
    J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340.
    

    >> Share

    
    
80. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
    Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
    J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
    

    >> Share

    
    January 2025
81. LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al
    Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
    J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574.
    

    >> Share

    
    
82. MADSEN C, Fuglo D, Pedersen M, Broholm R, et al
    Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
    J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275.
    

    >> Share

    
    
83. MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al
    Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System.
    J Nucl Med. 2025;66:75-83.
    

    >> Share

    
    
84. UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al
    Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
    J Nucl Med. 2025;66:54-60.
    

    >> Share

    
    
85. ZAID NRR, Bastiaannet R, Hobbs R, Sgouros G, et al
    Mathematic Modeling of Tumor Growth During [(177)Lu]Lu-PSMA Therapy: Insights into Treatment Optimization.
    J Nucl Med. 2025;66:84-90.
    

    >> Share

    
    
86. SCHWEIGER L, Maurer T, Simon R, Horn T, et al
    Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
    J Nucl Med. 2025;66:67-72.
    

    >> Share

    
    November 2024
87. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
    PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
    J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
    

    >> Share

    
    
88. WENZEL M, Koll F, Hoeh B, Humke C, et al
    Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
    

    >> Share

    
    
89. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
    SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
    

    >> Share

    
    
90. ZAGNI F, Vetrone L, Farolfi A, Vadala M, et al
    Feasibility of (177)Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer.
    J Nucl Med. 2024 Nov 7:jnumed.124.268062. doi: 10.2967/jnumed.124.268062.
    

    >> Share

    
    
91. SAIDI A, Stallons TA, Wong AG, Torgue JJ, et al
    Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.
    J Nucl Med. 2024;65:1769-1775.
    

    >> Share

    
    October 2024
92. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
    Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
    J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
    

    >> Share

    
    
93. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
    FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
    

    >> Share

    
    
94. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
    Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
    

    >> Share

    
    
95. MUNIZ M, Sartor O, Orme JJ, Koch RM, et al
    Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2024 Oct 30:jnumed.124.268277. doi: 10.2967/jnumed.124.268277.
    

    >> Share

    
    
96. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    

    >> Share

    
    
97. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    

    >> Share

    
    September 2024
98. MURTHY V, Voter AF, Nguyen K, Allen-Auerbach M, et al
    Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
    J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816.
    

    >> Share

    
    
99. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    

    >> Share

    
    
100. POULIOT F, Saad F, Rousseau E, Richard PO, et al
     Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
     J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
     

     >> Share

     
     
101. GAFITA A, Voter A, Shesadri S, Spitz A, et al
     Initial Experience with [(177)Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
     J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723.
     

     >> Share

     
     
102. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
     Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
     J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
     

     >> Share

     
     
103. POSCHENRIEDER A, Taleska J, Schaetz L
     (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
     J Nucl Med. 2024;65:1340-1342.
     

     >> Share

     
     
104. BELGE BILGIN G, Burkett BJ, Bilgin C, Orme JJ, et al
     Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.
     J Nucl Med. 2024;65:1402-1408.
     

     >> Share

     
     August 2024
105. WONG AJN, Ko HS, Hofman MS
     Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics Through the Lens of RELAINCE.
     J Nucl Med. 2024 Aug 29:jnumed.124.267924. doi: 10.2967/jnumed.124.267924.
     

     >> Share

     
     
106. THIN P, Hotta M, Gafita A, Grogan T, et al
     Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
     J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
     

     >> Share

     
     
107. HO KV, Tatum DS, Watkinson L, Carmack T, et al
     Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
     J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
     

     >> Share

     
     
108. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
     [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
     J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
     

     >> Share

     
     
109. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
     Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
     J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
     

     >> Share

     
     
110. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
     (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
     J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
     

     >> Share

     
     
111. LI S, Nguyen A, Counter W, John NC, et al
     Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
     J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
     

     >> Share

     
     
112. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
     Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
     

     >> Share

     
     
113. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
     Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
     J Nucl Med. 2024;65:1210-1216.
     

     >> Share

     
     July 2024
114. DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al
     Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
     J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658.
     

     >> Share

     
     
115. AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al
     Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
     J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477.
     

     >> Share

     
     
116. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
     (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
     J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
     

     >> Share

     
     
117. BUTEAU JP, Kostos L, Alipour R, Jackson P, et al
     Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [(161)Tb]Tb-PSMA-I&T.
     J Nucl Med. 2024 Jul 11:jnumed.124.267650. doi: 10.2967/jnumed.124.267650.
     

     >> Share

     
     
118. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
     Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
     J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
     

     >> Share

     
     
119. RATHKE H, Winter E, Bruchertseifer F, Rohrich M, et al
     Deescalated (225)Ac-PSMA-617 Versus (177)Lu/(225)Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
     J Nucl Med. 2024;65:1057-1063.
     

     >> Share

     
     June 2024
120. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
     Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
     J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
     

     >> Share

     
     
121. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
     Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
     J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
     

     >> Share

     
     
122. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
     A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
     J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
     

     >> Share

     
     
123. PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al
     Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of (99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
     J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450.
     

     >> Share

     
     
124. SEIFERT R, Telli T, Lapa C, Desaulniers M, et al
     Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German Multicenter Study.
     J Nucl Med. 2024;65:909-916.
     

     >> Share

     
     May 2024
125. PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al
     A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416.
     

     >> Share

     
     
126. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
     CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
     J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
     

     >> Share

     
     
127. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
     True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
     J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
     

     >> Share

     
     
128. ZANG J, Yang Y, Chen S, Wang C, et al
     Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
     J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
     

     >> Share

     
     
129. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
     Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
     J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
     

     >> Share

     
     
130. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
     Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
     J Nucl Med. 2024;65:735-739.
     

     >> Share

     
     April 2024
131. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
     Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
     J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
     

     >> Share

     
     
132. DUAN H, Song H, Davidzon GA, Moradi F, et al
     Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
     J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
     

     >> Share

     
     
133. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
     RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
     

     >> Share

     
     
134. HUANG YY, Lin TC, Yang SH, Lai LS, et al
     [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
     J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533.
     

     >> Share

     
     
135. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
     Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
     J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
     

     >> Share

     
     
136. VISCUSE P, Devitt M, Dreicer R
     Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
     J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
     

     >> Share

     
     
137. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
     Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
     J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
     

     >> Share

     
     
138. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
     Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
     J Nucl Med. 2024;65:566-572.
     

     >> Share

     
     March 2024
139. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
     Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
     J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
     

     >> Share

     
     
140. SHI J, Li D, Chen M, Fu Y, et al
     The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
     J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
     

     >> Share

     
     
141. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
     Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
     J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
     

     >> Share

     
     February 2024
142. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
     Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
     J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
     

     >> Share

     
     
143. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
     First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
     

     >> Share

     
     
144. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
     The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
     J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
     

     >> Share

     
     
145. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
     Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
     J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
     

     >> Share

     
     
146. MAURER T, Thomas C, Hadaschik B
     The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?
     J Nucl Med. 2024 Feb 15:jnumed.123.267187. doi: 10.2967/jnumed.123.267187.
     

     >> Share

     
     
147. KUMAR S, Crumbaker M, Emmett L
     Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2024;65:333-334.
     

     >> Share

     
     
148. ASKARI E, Harsini S
     Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2024;65:332-333.
     

     >> Share

     
     January 2024
149. LIGHT A, Lazic S, Houghton K, Bayne M, et al
     Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
     J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
     

     >> Share

     
     
150. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
     Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
     J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
     

     >> Share

     
     
151. RAHBAR K, Boegemann M
     The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
     J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
     

     >> Share

     
     
152. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
     PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
     J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
     

     >> Share

     
     
153. RAVI KUMAR AS, Hofman MS
     Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
     J Nucl Med. 2024;65:85-86.
     

     >> Share

     
     
154. STEINHELFER L, Lunger L, Cala L, Pfob CH, et al
     Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
     J Nucl Med. 2024;65:79-84.
     

     >> Share

     
     December 2023
155. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
     First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
     J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
     

     >> Share

     
     
156. BENABDALLAH N, Lu P, Abou DS, Zhang H, et al
     Beyond Average: alpha-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
     J Nucl Med. 2023 Dec 14:jnumed.123.266571. doi: 10.2967/jnumed.123.266571.
     

     >> Share

     
     
157. JADVAR H
     Sequential and Combination Therapies of (223)RaCl(2) and Prostate-Specific Membrane Antigen Radioligand Therapy.
     J Nucl Med. 2023;64:1932-1933.
     

     >> Share

     
     November 2023
158. EMMETT L, Papa N, Counter W, Calais J, et al
     Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
     J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
     

     >> Share

     
     
159. WANG F, Liu C, Vidal I, Mana-Ay M, et al
     Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
     J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
     

     >> Share

     
     
160. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
     Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
     J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
     

     >> Share

     
     
161. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
     Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
     J Nucl Med. 2023 Nov 30:jnumed.123.265448. doi: 10.2967/jnumed.123.265448.
     

     >> Share

     
     
162. SARTOR O, Ledet E, Huang M, Schwartz J, et al
     Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
     J Nucl Med. 2023;64:1721-1725.
     

     >> Share

     
     October 2023
163. RAHBAR K, Essler M, Eiber M, la Fougere C, et al
     (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
     J Nucl Med. 2023 Oct 12:jnumed.123.266125. doi: 10.2967/jnumed.123.266125.
     

     >> Share

     
     
164. MEYER C, Stuparu A, Lueckerath K, Calais J, et al
     Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer.
     J Nucl Med. 2023 Oct 5:jnumed.123.265433. doi: 10.2967/jnumed.123.265433.
     

     >> Share

     
     
165. TSCHAN VJ, Busslinger SD, Bernhardt P, Grundler PV, et al
     Albumin-Binding and Conventional PSMA Ligands in Combination with (161)Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
     J Nucl Med. 2023;64:1625-1631.
     

     >> Share

     
     
166. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
     Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
     J Nucl Med. 2023;64:1632-1637.
     

     >> Share

     
     
167. GRAVES SA
     Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [(177)Lu]Lu-PSMA-617.
     J Nucl Med. 2023;64:1567-1569.
     

     >> Share

     
     
168. MERCOLLI L, Mingels C, Manzini G, Cumming P, et al
     [(177)Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.
     J Nucl Med. 2023;64:1570-1573.
     

     >> Share

     
     September 2023
169. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
     PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
     J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
     

     >> Share

     
     
170. RINSCHEID A, Gable A, Wienand G, Pfob C, et al
     An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970.
     

     >> Share

     
     
171. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
     Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
     J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
     

     >> Share

     
     
172. SATAPATHY S, Mittal BR, Sood A, Das CK, et al
     [(177)Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.
     J Nucl Med. 2023 Sep 14:jnumed.123.266141. doi: 10.2967/jnumed.123.266141.
     

     >> Share

     
     
173. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
     Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
     J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
     

     >> Share

     
     
174. MURTHY V, Gafita A, Thin P, Nguyen K, et al
     Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
     J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
     

     >> Share

     
     
175. KUMAR S, Crumbaker M, Harvey C, Pathmanandavel S, et al
     The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2023;64:1412-1416.
     

     >> Share

     
     
176. MURTHY V, Allen-Auerbach M, Lam R, Owen D, et al
     PSMA-Negative Lesion Progression Under (177)Lu-PSMA Radioligand Therapy.
     J Nucl Med. 2023;64:1502-1503.
     

     >> Share

     
     
177. HOPE TA, Antonarakis ES, Bodei L, Calais J, et al
     SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-PSMA-617 Radionuclide Therapy.
     J Nucl Med. 2023;64:1417-1423.
     

     >> Share

     
     August 2023
178. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
     PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
     J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
     

     >> Share

     
     
179. HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al
     Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
     J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953.
     

     >> Share

     
     
180. HOPE TA, Benz M, Jiang F, Thompson D, et al
     Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
     J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916.
     

     >> Share

     
     July 2023
181. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
     Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
     J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523.
     

     >> Share

     
     
182. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
     Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
     J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771.
     

     >> Share

     
     
183. STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al
     Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
     J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share